Please login to the form below

Not currently logged in
Email:
Password:

Glycotope appoints Dr Alfredo Zurlo as chief medical officer

He joins the German clinical-stage immuno-oncology company from Mologen

Glycotope Alfredo ZurloGerman clinical-stage immuno-oncology company Glycotope has appointed Dr Alfredo Zurlo as chief medical officer.

He joins the firm from Mologen AG, where he was its chief medical officer and a member of the Berlin-based biotech's executive board.

Prior that Dr Zurlo held various positions at F Hoffmann La Roche and Roche SA, including senior international medical leader director oncology and medical director oncology.

Previous to his time at Roche he was a medical advisor for the European Organisation for the Research and Treatment of Cancer (EORTC).

Glycotope's chief executive officer Paul Higham said: “We are delighted that Alfredo has decided to join Glycotope. He has an exceptionally strong background in oncology both in a clinical setting and within companies developing and marketing treatments for cancer.

“His experience in designing and managing clinical trials will be invaluable as we continue to advance our mature and growing pipeline of proprietary cancer therapies including our oncology lead PankoMab-GEX which is currently in phase IIb in ovarian cancer.“

11th May 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics